Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Innate pharma sa symbols : AZN save search
Hairy Cell Leukemia Therapeutics Market Size to Grow by USD 177.85 million, Majority of Growth to Originate from North America - Technavio
Published: 2022-08-22 (Crawled : 07:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 2.39%
H: 1.09%
C: 1.09%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.66%
H: 0.1%
C: -1.43%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.08%
H: 0.49%
C: -1.15%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.49%
H: 1.11%
C: -0.39%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.35%
H: 0.5%
C: -1.23%
america leukemia therapeutics growth market
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
Published: 2022-08-01 (Crawled : 10:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: -14.87%
H: 4.09%
C: 4.09%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -3.9%
H: 0.0%
C: 0.0%
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -0.21%
H: 0.41%
C: -0.73%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
IPHA | $2.4 -0.42% -0.42% 11K
|
Health Technology
|
| O: -11.25%
H: 0.0%
C: -1.06%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.44%
H: 0.53%
C: -1.31%
pharma update study
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
Published: 2022-06-03 (Crawled : 08:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: -0.32%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 0.65%
H: 0.63%
C: 0.16%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
IPHA | $2.4 -0.42% -0.42% 11K
|
Health Technology
|
| O: 2.96%
H: 0.98%
C: -1.15%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.56%
H: 0.82%
C: -0.64%
iph5201 pharma cancer phase 2
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
Published: 2022-04-29 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 5.98%
H: 1.44%
C: -0.42%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
IPHA | $2.4 -0.42% -0.42% 11K
|
Health Technology
|
| O: 11.11%
H: 3.67%
C: -4.33%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.53%
H: 2.37%
C: 0.26%
trial payment cancer phase 3
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.